Macrogenics (MGNX) EBITDA Margin (2012 - 2026)

Macrogenics (MGNX) has 15 years of EBITDA Margin data on file, last reported at 177.29% in Q1 2026.

• EBITDA Margin for Q1 2026 came in at 177.29%, up 13381.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 44.81% (down 1145.0% YoY), and the FY2025 annual result was 49.89%, down 525.0% from the prior year.
• EBITDA Margin retreated to 177.29% in Q1 2026 per MGNX's latest filing, from 34.27% in the prior quarter.
• Over five years, EBITDA Margin peaked at 436.88% in Q2 2023 and troughed at 1686.45% in Q2 2024.
• A 5-year average of 217.04% and a median of 155.11% in 2023 frame the typical range for EBITDA Margin.
• The sharpest annual moves came in 2024 and 2025: EBITDA Margin plunged 212334 bps in 2024, then surged 152344 bps in 2025.
• A 5-year view of EBITDA Margin shows it stood at 17.66% in 2022, then tumbled by 2532 bps to 429.51% in 2023, then soared by 91 bps to 38.58% in 2024, then gained by 11 bps to 34.27% in 2025, then slumped by 417 bps to 177.29% in 2026.
• Business Quant data shows MGNX's EBITDA Margin at 177.29% in Q1 2026, 34.27% in Q4 2025, and 23.11% in Q3 2025.